Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib

Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart[...]

Bae EB, Kim MY, Ji S, Cho IW, Kim SY, Esmaeili M, Baik SS, Kim S, Tetradis S, Park NH, Gwack Y, Kim RH. Anti-VEGF[...]

Sasaki K, Bhatia V, Asano Y, Bakhtiari J, Kaur P, Wang C, Matsuo T, Dubois O, Chiu PC, Gun D, Singh C, Panagi I, Noblecourt[...]